Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VTX3232 Dose A · 1 trial · 1 indication
Incidence of AEs and SAEs and AEs leading to study treatment discontinuation
| Arm | Type | Description |
|---|---|---|
| VTX3232 Dose A | EXPERIMENTAL | VTX3232 Dose A |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| VTX3232 Dose A in combination with semaglutide | EXPERIMENTAL | VTX3232 Dose A in combination with semaglutide |
| Placebo in combination with semaglutide | EXPERIMENTAL | Placebo in combination with semaglutide |
| Name | Type | Description |
|---|---|---|
| VTX3232 Dose A | DRUG | VTX3232 Dose A |
| Placebo | DRUG | Placebo |
| VTX3232 Dose A in combination with semaglutide | DRUG | VTX3232 Dose A in combination with semaglutide |
| Placebo in combination with semaglutide | DRUG | Placebo in combination with semaglutide |
Inclusion Criteria: * Participants are male or female ≥ 18 years up to ≤ 80 years of age. * Ability to comply with study requirements. * BMI ≥ 30.0 to ≤ 42.0 kg/m2 at screening. * Stable body weight (± 5%) for at least 3 months prior to screening. * hs-CRP ≥ 2 mg/L at screening. * Hypertension or h...
Top 20 of 32 competitors
VTX3232 Dose A is an investigational small molecule being studied for the treatment of obesity. It is being evaluated in a Phase 2a clinical trial, both alone and in combination with semaglutide, in adult patients with obesity. The drug is not yet approved and remains in clinical development.
VTX3232 Dose A is being developed by Ventyx Biosciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol VTYX. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for obesity.
VTX3232 Dose A is in Phase 2 clinical development. Specifically, it is being studied in a Phase 2a placebo-controlled trial for obesity. The trial has been completed, but the drug remains investigational and has not received FDA approval.
VTX3232 Dose A is being studied in clinical trial NCT06771115, a Phase 2a placebo-controlled study of VTX3232 alone or in combination with semaglutide in obesity. This randomized, double-blind trial enrolled 176 participants in the United States and has been completed.
VTX3232 Dose A is a specific dose of the investigational drug VTX3232. The clinical trial NCT06771115 evaluates VTX3232, including the Dose A regimen, for the treatment of obesity. The drug is being developed by Ventyx Biosciences and is not yet approved.